We are live on ! Find out more
ELEV

Elevation Oncology
ELEV

Delisted

ELEV was delisted on the 22nd of July, 2025.

Back to rankings

39 hedge funds and large institutions have $47.9M invested in Elevation Oncology in 2023 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 8 increasing their positions, 5 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 6

60.95% more ownership

Funds ownership: 68.62% → 129.57% (+61%)

60% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 5

55% more capital invested

Capital invested by funds: $30.9M → $47.9M (+$17.1M)

44% more funds holding

Funds holding: 27 → 39 (+12)

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

Holders
39
Holders Change
+12
Holders Change %
+44.44%
% of All Funds
0.61%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
18
Increased
8
Reduced
5
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$6.86M
2
AC
Armistice Capital
New York
+$6.32M
3
Millennium Management
Millennium Management
New York
+$6.11M
4
O
OrbiMed
New York
+$3.96M
5
ECM
ExodusPoint Capital Management
New York
+$3.95M

Top Sellers

Rank Fund Capital Flow
1
CAM
Cormorant Asset Management
Massachusetts
-$3.71M
2
SCM
Sio Capital Management
New York
-$1.67M
3
Walleye Capital
Walleye Capital
New York
-$872K
4
Morgan Stanley
Morgan Stanley
New York
-$382K
5
KCM
Kennedy Capital Management
Missouri
-$284K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
1
Tang Capital Management
California
$6.08M +$6.86M +2,600,000 +186%
VP
2
venBio Partners
California
$4.43M +$2.76M +1,047,916 +56%
ACM
3
Aisling Capital Management
New York
$4.31M – – –
AC
4
Armistice Capital
New York
$3.64M +$6.32M +2,396,000 New
QUSVM
5
Qiming U.S. Ventures Management
Washington
$3.6M – – –
Millennium Management
6
Millennium Management
New York
$3.52M +$6.11M +2,316,426 New
BI
7
BVF Inc
California
$3.51M – – –
O
8
OrbiMed
New York
$2.28M +$3.96M +1,500,000 New
ECM
9
ExodusPoint Capital Management
New York
$2.28M +$3.95M +1,499,319 New
DM
10
Deerfield Management
New York
$2.1M +$3.64M +1,381,416 New
IC
11
Ikarian Capital
Texas
$1.75M +$3.03M +1,149,490 New
Vanguard Group
12
Vanguard Group
Pennsylvania
$1.63M +$1.63M +619,376 +136%
SFM
13
Sphera Funds Management
Israel
$1.37M +$2.37M +900,000 New
Citadel Advisors
14
Citadel Advisors
Florida
$1.27M +$2.21M +838,594 New
SB
15
Samsara BioCapital
California
$1.26M – – –
Hudson Bay Capital Management
16
Hudson Bay Capital Management
Connecticut
$830K +$1.44M +546,294 New
VCIM
17
Velan Capital Investment Management
Georgia
$756K +$1.31M +497,299 New
DCM
18
DAFNA Capital Management
California
$684K +$1.19M +450,000 New
Two Sigma Investments
19
Two Sigma Investments
New York
$644K +$923K +349,937 +473%
Point72 Asset Management
20
Point72 Asset Management
Connecticut
$608K +$1.05M +400,000 New
BFM
21
Boothbay Fund Management
New York
$356K +$618K +234,266 New
Geode Capital Management
22
Geode Capital Management
Massachusetts
$207K +$15.3K +5,785 +4%
SSA
23
Schonfeld Strategic Advisors
New York
$204K +$354K +134,100 New
Walleye Capital
24
Walleye Capital
New York
$158K -$872K -330,818 -76%
BCM
25
Bridgeway Capital Management
Texas
$85.9K – – –
1
2

ELEV Hedge Fund Activity: Q2 2023 in Review

39 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Elevation Oncology (ELEV) for Q2 2023, worth a combined $47.9M — up 55% from $30.9M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new ELEV positions and 6 closed out — a net gain of 12 holders — while 8 added to existing stakes and 5 trimmed.

The largest buyer was Tang Capital Management, adding an estimated $6.86M. The largest seller was Cormorant Asset Management, exiting entirely with an estimated $3.71M sold.

  • 39 institutional investors held Elevation Oncology (ELEV) as of Q2 2023, up from 27 in Q1 2023.
  • Funds reported $47.9M of Elevation Oncology stock for Q2 2023, up 55% quarter-over-quarter.
  • 18 funds opened new Elevation Oncology positions in Q2 2023 and 6 closed out, a net change of +12 holders.
  • The largest Elevation Oncology buyer in Q2 2023 was Tang Capital Management, an estimated $6.86M added.
  • The largest Elevation Oncology seller in Q2 2023 was Cormorant Asset Management, an estimated $3.71M sold.

Based on aggregated 13F filings for Q2 2023.